Artisan Partners Limited Partnership Boosts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

Artisan Partners Limited Partnership lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 3.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 558,326 shares of the company’s stock after acquiring an additional 19,023 shares during the quarter. Artisan Partners Limited Partnership owned approximately 1.32% of Tarsus Pharmaceuticals worth $33,181,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Federated Hermes Inc. boosted its position in shares of Tarsus Pharmaceuticals by 0.6% in the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock worth $2,229,000 after purchasing an additional 339 shares during the period. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of Tarsus Pharmaceuticals by 6.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,626 shares of the company’s stock valued at $349,000 after buying an additional 505 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Tarsus Pharmaceuticals by 9.6% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 8,438 shares of the company’s stock worth $342,000 after buying an additional 740 shares during the period. Franklin Resources Inc. boosted its holdings in Tarsus Pharmaceuticals by 3.6% in the 2nd quarter. Franklin Resources Inc. now owns 21,402 shares of the company’s stock worth $867,000 after buying an additional 750 shares during the period. Finally, Profund Advisors LLC increased its stake in Tarsus Pharmaceuticals by 12.7% in the 2nd quarter. Profund Advisors LLC now owns 9,469 shares of the company’s stock worth $384,000 after buying an additional 1,064 shares in the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TARS has been the topic of several research analyst reports. Guggenheim boosted their price objective on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday. Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.00.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS opened at $75.52 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.85 and a quick ratio of 4.25. Tarsus Pharmaceuticals, Inc. has a 1-year low of $38.51 and a 1-year high of $85.25. The business has a 50 day simple moving average of $72.00 and a two-hundred day simple moving average of $68.73. The stock has a market capitalization of $3.21 billion, a PE ratio of -46.62 and a beta of 0.57.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The firm had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million. On average, research analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Key Headlines Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Guggenheim set a new $90.00 price target for TARS, signaling confidence in long-term upside if the company executes on growth drivers. Guggenheim Price Target
• Positive Sentiment: Oppenheimer issued a favorable forecast for Tarsus’ stock, which may provide support if sentiment shifts back toward growth expectations. Oppenheimer Forecast
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences — an opportunity to update investors on commercialization progress and future guidance. Investor Conferences Release
• Neutral Sentiment: Analysis pieces are debating whether the market has rerated TARS too cautiously after adoption headlines for XDEMVY, offering a counterpoint to the negative analyst actions but not delivering hard new catalysts. Yahoo Analysis
• Negative Sentiment: HC Wainwright sharply reduced near-term and multi-year EPS forecasts (Q1–Q4 2026 and FY2026–FY2029), cutting assumptions for revenue/earnings ramp — this is the primary downward pressure on the shares today. HC Wainwright Estimates Summary
• Negative Sentiment: Zacks Research downgraded TARS from “strong-buy” to “hold,” which can trigger selling from momentum/quant funds and heighten near-term caution among retail investors. Zacks Downgrade

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 7,397 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total transaction of $592,499.70. Following the completion of the transaction, the insider owned 38,958 shares in the company, valued at $3,120,535.80. This trade represents a 15.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total transaction of $495,060.00. Following the sale, the chief executive officer owned 857,991 shares in the company, valued at $70,792,837.41. This represents a 0.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 8.97% of the stock is owned by company insiders.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.